Wednesday, July 8, 2026

Patent intelligence · US

US 10213488

Delivery of therapeutic agents by a collagen binding protein

granted A61KA61K38/29A61K38/48A61K47/56
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 13
Applicant portfolio 72
Patent details — US 10213488
Jurisdiction
US
Status
granted
Grant date
Feb 26, 2019
Expiration
Feb 21, 2039
Claims
11
CPC classes
A61K, A61K38/29, A61K38/48, A61K47/56
View on Google Patents ↗

Quick answer

US 10213488 (Delivery of therapeutic agents by a collagen binding protein) is held by Montefiore Medical Center. Status: granted. Granted Feb 26, 2019. Expires Feb 21, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
11
CPC classes
A61K, A61K38/29, A61K38/48, A61K47/56, A61K47/64, A61P

More from Montefiore Medical Center

Related pharmaceutical patents in our USPTO index.

  1. US 12391663

    Isoindolinone compounds

    Monte Rosa Therapeutics AG · Expires Aug 14, 2045

    granted
  2. US 12378199

    Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules

    UNIVERSITÀ DEGLI STUDI DEL PIEMONTE ORIENTALE “A. AVOGADRO” · Expires Jul 31, 2045

    granted
  3. US 12280029

    Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

    INSTITUT PASTEUR DE MONTEVIDEO · Expires Apr 17, 2045

    granted
  4. US 12263143

    Ionic channel modulation as a method for treating tumors through inflammasome activation

    INSTITUT PASTEUR DE MONTEVIDEO · Expires Mar 27, 2045

    granted
  5. US 12257247

    Targeted degradation of VAV1

    Monte Rosa Therapeutics AG · Expires Mar 20, 2045

    granted
  6. US 12214218

    Perfusion modulated tumor dose sculpting with single dose radiotherapy

    FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · Expires Jan 30, 2045

    granted
  7. US 12070628

    Low energy immune priming for treating cancer and metastasis

    Montefiore Medical Center · Expires Aug 22, 2044

    granted
  8. US 12011619

    Low intensity focused ultrasound for treating cancer and metastasis

    Montefiore Medical Center · Expires Jun 13, 2044

    granted

Frequently asked questions

What is US patent 10213488?

US 10213488 (Delivery of therapeutic agents by a collagen binding protein) is held by Montefiore Medical Center. Status: granted. Granted Feb 26, 2019. Expires Feb 21, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10213488?

Montefiore Medical Center is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.

When does US 10213488 expire?

Our index shows an expiration date of Feb 21, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.